Cohance Lifesciences Ltd.
Research Cohance Lifesciences Ltd. (COHANCE.NS) on Bullrun: market cap INR 177.54B, P/E 170.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCOHANCE.NS
- ExchangeNSE
- CountryIndia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyINR
- Market capINR 177.54B
- P/E170.0
- Financial periodQ2 2026
- RevenueINR 4.22B
- Net income-INR 241.20M
- Gross margin71.5%
Valuation Snapshot
latest market cap is INR 177.54B; P/E is 170.0.
Peer valuation comparison
Latest P/E is 169.98x versus a Healthcare sector median of 21.74x (681.7% above).
Latest P/E is 169.98x versus a India median of 34.43x (393.7% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | INR 177.54B | 170.0 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 INR.
About Cohance Lifesciences Ltd.
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cohance Lifesciences Ltd.'s market cap?
Cohance Lifesciences Ltd.'s market capitalization is INR 177.54B.
What is Cohance Lifesciences Ltd.'s P/E ratio?
Cohance Lifesciences Ltd.'s price-to-earnings (P/E) ratio is 170.0.
What does Cohance Lifesciences Ltd. do?
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally.